Track NanoVibronix, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NanoVibronix, Inc. NAOV Open NanoVibronix, Inc. in new tab

1.90 USD
EPS
-51.81
P/B
0.10
ROE
-30.51
Beta
2.06
Loading chart...
Key Metrics
Earnings dateMay 18, 2026
EPS-51.81
Book Value42.00
Price to Book0.10
Debt/Equity7.47
% Insiders0.761%
Growth
Revenue Growth0.92%
Estimates
Forward P/E-4.96
Forward EPS-0.81

DCF Valuation

Tweak assumptions to recompute fair value for NanoVibronix, Inc. (NAOV)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NanoVibronix, Inc. Logo NanoVibronix, Inc. Analysis (NAOV)

United States Health Care Official Website Stock

Is NanoVibronix, Inc. a good investment? NanoVibronix, Inc. (NAOV) is currently trading at 1.90 USD.

Earnings Schedule: NanoVibronix, Inc. is expected to release its next earnings report on May 18, 2026. The market consensus estimate for Forward EPS is -0.81.

Investor FAQ

Does NanoVibronix, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NanoVibronix, Inc.?

NanoVibronix, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 18, 2026. The company currently has a trailing EPS of -51.81.

Company Profile

NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.

Exchange Ticker
NMS (United States) NAOV

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Aug. 12, 2025 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion